Clinical Trials Search at Vanderbilt-Ingram Cancer Center
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL)
Multiple Cancer Types
This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL / LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to assess the tolerability and efficacy of JZP-458 (only in patients who develop hypersensitivity to an E. coli-derived asparaginase), as measured by asparaginase activity.
Pediatric Leukemia, Pediatric Lymphoma, Pediatrics